US 12,076,396 B2
Steroid acid-based immunogen enhancers
Simon Beaudoin, Sherbrooke (CA)
Assigned to DEFENCE THERAPEUTICS INC., Vancouver (CA)
Filed by DEFENCE THERAPEUTICS INC., Vancouver (CA)
Filed on Feb. 15, 2023, as Appl. No. 18/169,440.
Application 18/169,440 is a continuation of application No. 17/738,548, filed on May 6, 2022, granted, now 11,612,651.
Claims priority of provisional application 63/362,494, filed on Apr. 5, 2022.
Claims priority of provisional application 63/201,620, filed on May 6, 2021.
Prior Publication US 2023/0233673 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/385 (2006.01); A61K 47/54 (2017.01); A61K 47/64 (2017.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/385 (2013.01) [A61K 47/542 (2017.08); A61K 47/554 (2017.08); A61K 47/64 (2017.08); A61P 31/14 (2018.01); A61K 2039/6006 (2013.01); A61K 2039/6031 (2013.01)] 20 Claims
 
1. A composition comprising a polypeptide antigen admixed with an enhancer of antigen-presentation, the enhancer comprising a steroid acid-peptide conjugate in an amount sufficient to improve presentation of the polypeptide antigen upon administration of the composition to antigen-presenting cells, as compared to administration of a corresponding composition lacking the enhancer, wherein the peptide comprised in the steroid acid-peptide conjugate comprises a nuclear localization signal (NLS), and wherein the peptide comprised in the steroid acid-peptide conjugate is a non-immunogenic peptide.